Immunogenicity after heterologous third dose COVID-19 vaccination in a heart transplant recipient

Clin Transplant. 2022 Apr;36(4):e14605. doi: 10.1111/ctr.14605. Epub 2022 Feb 11.

Authors

Sapna A Mehta^{1

2}, Alex Reyentovich^{1

2}, Robert A Montgomery^{1

2}, Dorry L Segev³, Howard M Gebel⁴, Robert A Bray⁴, Marie I Samanovic^{2

5}, Amber R Cornelius^{2

5}, Mark J Mulligan^{2

5}, Ramin S Herati^{2

5}

Affiliations

¹ New York University Langone Transplant Institute, New York, New York, USA.
² New York University Grossman School of Medicine, New York, New York, USA.
³ Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
⁴ Department of Pathology, Emory University Hospital, Atlanta, Georgia, USA.
⁵ New York University Langone Vaccine Center, New York, New York, USA.

PMID: 35107835
DOI: 10.1111/ctr.14605

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Viral
COVID-19 Vaccines
COVID-19* / epidemiology
COVID-19* / prevention & control
Heart Transplantation*
Humans
Vaccination

Substances

Antibodies, Viral
COVID-19 Vaccines